Thrombosis Outcomes in Pediatric Venous Thromboembolism (TOP)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03068923 |
|
Recruitment Status :
Recruiting
First Posted : March 3, 2017
Last Update Posted : March 3, 2017
|
Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
National Heart, Lung, and Blood Institute (NHLBI)
Information provided by (Responsible Party):
Ayesha Zia, University of Texas Southwestern Medical Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
'The TOP Study' is a prospective cohort study whose main objective is to develop better prognostic biomarkers and identify children at risk of adverse thrombotic outcomes very early in the course after an initial venous thromboembolic events (VTE). The study will compare biomarkers in children that develop poor VTE outcomes (such as recurrence, postthrombotic syndrome and post PE impairment ) after an initial VTE with those that do not develop such outcomes.
| Condition or disease |
|---|
| Venous Thromboembolism |
All newly diagnosed patients with a first radiologically confirmed thrombotic event (any site) diagnosed at Children's Medical Center, Dallas will be followed prospectively with global coagulation assessment over a 24-month period, and monitored for development of carefully defined adverse VTE outcomes in a blinded manner. Biomarker assessment will include global coagulation assays (thrombin generation assay and modified thromboelastography to study fibrinolysis) at 3, 6, 12, 18 and 24 months post VTE diagnosis.
| Study Type : | Observational |
| Estimated Enrollment : | 200 participants |
| Observational Model: | Cohort |
| Time Perspective: | Prospective |
| Official Title: | Predicting and Preventing Poor Outcomes of Venous Thromboembolism in Children |
| Actual Study Start Date : | May 2016 |
| Estimated Primary Completion Date : | April 2020 |
| Estimated Study Completion Date : | April 2021 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Blood Clots
Primary Outcome Measures :
- Postthrombotic syndrome (PTS) [ Time Frame: within 24 months after diagnosis of VTE ]PTS as assessed by the validated Manco-Johnson and the modified Villata PTS instruments determined a priori and confirmed by an endpoint adjudicating committee
- Symptomatic recurrent venous thromboembolism [ Time Frame: within 24 months after diagnosis of VTE ]Recurrent VTE as assessed by ISTH proposed recurrent VTE clinical criteria
- Post-pulmonary embolism (PE) impairment [ Time Frame: within 24 months after diagnosis of VTE ]Post-PE impairment as assessed by evidence of pulmonary hypertension/right ventricular dysfunction on echocardiography and/or impaired functional parameters on six-minute walking distance
Secondary Outcome Measures :
- Post-thrombotic sequelae [ Time Frame: Within 24 months after diagnosis of VTE ]Site specific sequelae after cerebral sinus venous, portal vein and renal vein thrombosis as assessed by ISTH recommended guidelines
- Change in quality of life [ Time Frame: Within 24 months after diagnosis of VTE ]Quality of life by PedsQL (TM)
Other Outcome Measures:
- Change in Physical Activity scores [ Time Frame: Within 24 months after diagnosis of VTE ]Physical activity as determined by Gordin questionnaire
- Elastic Compression Stocking (ECS) use over time [ Time Frame: Within 24 months after diagnosis of VTE ]ECS use will be assessed by ECS log/diary documenting dedicated (use for at least 6 days/week), moderate (use for 4-5 days/week) or poor use (<4 days/week)
- Loss of venous access [ Time Frame: 12 months post DVT diagnosis ]Loss of venous access in subjects with catheter related DVT of the upper extremity DVT as defined by >30% of the narrowing of the involved vein as assessed by doppler ultrasound or contrast venography
- Venous valvular reflux [ Time Frame: 12 months post DVT diagnosis ]Venous valvular reflux in subjects with lower extremity DVT will be assessed as present (>0.5 seconds) or absent (<0.5 seconds) at the 12 month post diagnosis visit with a standardized venous reflux ultrasound procedure
Biospecimen Retention: Samples With DNA
Plasma and DNA samples
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 21 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Newly diagnosed patients with first venous thromboembolism who have completed therapeutic anticoagulant therapy
Criteria
Inclusion Criteria:
- Boys and girls age birth (0 years) to equal to or less than 21 years
- A radiologically confirmed first venous thromboembolism episode (both extremity and non-extremity) who have completed anticoagulation therapy as per the 9th edition of the ACCP guidelines
Exclusion Criteria:
- Known malignancy
- Pregnancy or immediate post-partum period (12 weeks after delivery)
- Sickle cell disease
- Known bleeding disorder
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03068923
Contacts
| Contact: Kendra Malone, MPH | 214-456-3359 | kendra.malone@childrens.com | |
| Contact: Anna Winborn, CCRC | 214-456-8185 | anna.winborn@childrens.com |
Locations
| United States, Texas | |
| Children's Medical Center | Recruiting |
| Dallas, Texas, United States, 75235 | |
| Contact: Ayesha Zia, MD ayesha.zia@utsouthwestern.edu | |
Sponsors and Collaborators
University of Texas Southwestern Medical Center
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
| Principal Investigator: | Ayesha Zia, M.D. | University of Texas Southwestern Medical Center |
| Responsible Party: | Ayesha Zia, Assistant Professor of Pediatrics, University of Texas Southwestern Medical Center |
| ClinicalTrials.gov Identifier: | NCT03068923 History of Changes |
| Other Study ID Numbers: |
STU 122015-029 1K23HL132054-01 ( U.S. NIH Grant/Contract ) |
| First Posted: | March 3, 2017 Key Record Dates |
| Last Update Posted: | March 3, 2017 |
| Last Verified: | February 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No | |
| Studies a U.S. FDA-regulated Device Product: | No | |
Keywords provided by Ayesha Zia, University of Texas Southwestern Medical Center:
|
Blood clot Deep Vein Thrombosis Pulmonary Embolism Lower Extremity Upper Extremity Cerebral sinus Renal vein Portal vein |
thrombin fibrinolysis coagulation anticoagulation Post trombotic syndrome Post pulmonary embolism syndrome Chronic thromboembolic pulmonary hypertension |
Additional relevant MeSH terms:
|
Thromboembolism Venous Thromboembolism Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases |